- Home
- TSLX vs KNSA Comparison
TSLX vs KNSA Comparison
Compare TSLX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- KNSA
- Stock Information
- Founded
- TSLX 2010
- KNSA 2015
- Country
- TSLX United States
- KNSA United Kingdom
- Employees
- TSLX N/A
- KNSA N/A
- Industry
- TSLX Investment Managers
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TSLX Finance
- KNSA Health Care
- Exchange
- TSLX Nasdaq
- KNSA Nasdaq
- Market Cap
- TSLX 2.0B
- KNSA 1.9B
- IPO Year
- TSLX 2014
- KNSA 2018
- Fundamental
- Price
- TSLX $23.30
- KNSA $27.36
- Analyst Decision
- TSLX Strong Buy
- KNSA Strong Buy
- Analyst Count
- TSLX 8
- KNSA 5
- Target Price
- TSLX $22.69
- KNSA $38.80
- AVG Volume (30 Days)
- TSLX 473.3K
- KNSA 474.9K
- Earning Date
- TSLX 07-30-2025
- KNSA 07-22-2025
- Dividend Yield
- TSLX 7.90%
- KNSA N/A
- EPS Growth
- TSLX N/A
- KNSA N/A
- EPS
- TSLX 1.89
- KNSA N/A
- Revenue
- TSLX $481,092,000.00
- KNSA $481,166,000.00
- Revenue This Year
- TSLX N/A
- KNSA $37.21
- Revenue Next Year
- TSLX N/A
- KNSA $5.32
- P/E Ratio
- TSLX $12.33
- KNSA N/A
- Revenue Growth
- TSLX 4.73
- KNSA 59.45
- 52 Week Low
- TSLX $18.58
- KNSA $17.38
- 52 Week High
- TSLX $23.67
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- TSLX 70.00
- KNSA 62.48
- Support Level
- TSLX $22.35
- KNSA $26.28
- Resistance Level
- TSLX $23.06
- KNSA $27.90
- Average True Range (ATR)
- TSLX 0.38
- KNSA 0.99
- MACD
- TSLX 0.10
- KNSA -0.07
- Stochastic Oscillator
- TSLX 99.17
- KNSA 82.30
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.